International Journal of Medical Sciences And Clinical Research (ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Publisher: Oscar Publishing Services

Journal Website: https://theusajournals.com/index.php/ijmscr

Research Article

METABOLIC SYNDROME AND ITS PHARMACOTHERAPY AT THE MODERN LEVEL

Submission Date: May 13, 2024, Accepted Date: May 18, 2024,
Published Date: May 23, 2024
Crossref doi: https://doi.org/10.37547/ijmscr/Volume04Issue05-07

Muradova Railya Rustamovna
Assistant At The Department Of Clinical Pharmacology Samarkand State Medical University, Samarkand, Uzbekistan

ABSTRACT

Metabolic syndrome is a group of conditions that occur together and increase the risk of heart disease, stroke and type 2 diabetes. These conditions include high blood pressure, high blood sugar, excess fat around the waist and abnormal cholesterol levels. The prevalence of metabolic syndrome is steadily increasing worldwide, with an estimated 25% of adults worldwide affected. Pharmacotherapy plays a critical role in the treatment of metabolic syndrome to control individual components of the syndrome and reduce the risk of cardiovascular disease and other complications. Treatment for metabolic syndrome usually involves a combination of lifestyle changes such as diet and exercise and medications to control blood pressure, blood sugar, and cholesterol levels.

KEYWORDS

Metabolic syndrome, pharmacotherapy, biologically active substances, treatment.

INTRODUCTION

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes. These conditions include high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels.

Metabolic syndrome can have serious consequences on the body, such as increasing the risk of cardiovascular disease, kidney disease, and non-alcoholic fatty liver disease. It can also lead to insulin resistance, which is a precursor to developing type 2 diabetes.

International Journal of Medical Sciences And Clinical Research
(ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Crossref doi Google Scholar WorldCat MENDELEY
Publisher: Oscar Publishing Services

Treatment for metabolic syndrome often involves lifestyle changes such as adopting a healthy diet, increasing physical activity, and losing weight. However, in some cases, medication may be necessary to control blood pressure, blood sugar, and cholesterol levels.

There are several medications available for the treatment of metabolic syndrome, including statins to lower cholesterol, antihypertensive drugs to control blood pressure, and insulin sensitizers to improve insulin resistance. These medications are typically prescribed based on individual risk factors and health status.

Overall, the management of metabolic syndrome involves a multidisciplinary approach that includes healthcare professionals such as physicians, dietitians, and exercise specialists. By addressing the underlying conditions associated with metabolic syndrome, individuals can reduce their risk of developing serious complications and improve their overall health and well-being.

One of the key drugs used in the treatment of metabolic syndrome is statins, which are used to lower cholesterol levels and reduce the risk of cardiovascular disease. Statins work by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol synthesis. Several large clinical trials have demonstrated the effectiveness of statins in reducing the risk of heart attacks, strokes, and other cardiovascular events in patients with metabolic syndrome.

Another class of medications commonly used in the treatment of metabolic syndrome are antihypertensive drugs such as ACE inhibitors, beta-blockers, and diuretics. These medications help lower blood pressure and reduce the risk of heart disease and stroke. In addition, drugs such as metformin and thiazolidinediones are used to control blood sugar levels in patients with metabolic syndrome and reduce the risk of developing type 2 diabetes.

Purpose of the study: to study the role and significance of pharmacotherapy in people with metabolic syndrome.

Recent advances in pharmacotherapy for metabolic syndrome have focused on the development of new drugs that simultaneously target multiple components of the syndrome. For example, combination therapy that includes a statin, an antihypertensive drug, and an antidiabetic drug in one tablet has been shown to improve medication adherence and reduce the risk of cardiovascular events in patients with metabolic syndrome.

Metabolic syndrome is a collection of various risk factors, including obesity, hyperglycemia, hypertension, and dyslipidemia, that increase the likelihood of developing cardiovascular disease and

International Journal of Medical Sciences And Clinical Research (ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Publisher: Oscar Publishing Services

type 2 diabetes. This article discusses the main aspects of metabolic syndrome, its pathogenesis, diagnosis, and pharmacotherapy at the modern level. Metabolic syndrome is a major public health problem because it increases the risk of cardiovascular disease and other complications. One of the key points in the treatment of metabolic syndrome is pharmacotherapy aimed at controlling individual components of the syndrome to reduce the risk of developing cardiovascular complications.

Mechanisms of metabolic syndrome include insulin resistance, chronic inflammation, genetic factors, and an imbalance between fat and glucose metabolism. Insulin resistance plays a key role in the pathogenesis of metabolic syndrome, leading to disturbances in the metabolism of carbohydrates and fats, as well as the development of atherosclerosis. To diagnose metabolic syndrome, criteria are used that include the presence of three or more components: obesity, hyperglycemia, arterial hypertension, and dyslipidemia. Additional diagnostic methods include measuring insulin levels, assessing inflammatory markers, and testing endothelial function.

Pharmacotherapy for metabolic syndrome includes using various drugs to lower cholesterol levels, control blood pressure, and improve insulin sensitivity. Statins, blood pressure-lowering drugs, and antidiabetic drugs are the main drugs used in the treatment of metabolic syndrome.

Pharmacotherapy

Medications used to treat metabolic syndrome may include:

- Antihypertensive drugs to lower blood pressure
- Statins to lower LDL cholesterol levels
- Antidiabetic drugs to lower blood sugar levels
- Weight loss medications to promote weight loss
- Aspirin to reduce the risk of blood clots

In addition to medication, lifestyle changes are essential for managing metabolic syndrome and reducing the risk of complications. These changes include:

- Losing weight even a small amount of weight loss can improve blood pressure, cholesterol, and blood sugar levels
- Eating a healthy diet that is low in saturated and trans fats, cholesterol, sodium, and added sugars, and high in fruits, vegetables, and whole grains
- Getting regular exercise at least 30 minutes of moderate-intensity exercise most days of the week
- Quitting smoking
- Limiting alcohol consumption

International Journal of Medical Sciences And Clinical Research (ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Publisher: Oscar Publishing Services

Metabolic syndrome is a serious condition that can increase the risk of serious health problems. However, it is a manageable condition with lifestyle changes and medication. If you have been diagnosed with metabolic syndrome, it is important to work with your doctor to develop a treatment plan that is right for you.

CONCLUSION

Metabolic syndrome is a serious public health problem that requires a comprehensive approach to treatment. Pharmacotherapy plays an important role in the treatment of metabolic syndrome, helping to control individual components of the syndrome and reduce the risk of developing cardiovascular complications. Further research is needed to improve the effectiveness of pharmacotherapy for metabolic syndrome and reduce its global burden. In conclusion, pharmacotherapy plays a critical role in the treatment of metabolic syndrome, with a focus on controlling individual components of the syndrome to reduce the risk of cardiovascular disease and other complications.

REFERENCES

1. Han T. S., Lean M. E. J. Metabolic syndrome //Medicine. – 2015. – Т. 43. – №. 2. – С. 80-87.
2. Godswill A. G. et al. Health benefits of micronutrients (vitamins and minerals) and their associated deficiency diseases: A systematic review //International Journal of Food Sciences. – 2020. – Т. 3. – №. 1. – С. 1-32.
3. Cornier M. A. et al. The metabolic syndrome //Endocrine reviews. – 2008. – Т. 29. – №. 7. – С. 777-822.
4. Аскарова Ф., Яхшиноров И. ВЛИЯНИЕ МЕТАБОЛИЧЕСКИХ ИЗМЕНЕНИЙ НА СЕРДЕЧНО-СОСУДИСТУЮ СИСТЕМУ ЖЕНЩИН //Евразийский журнал медицинских и естественных наук. – 2024. – Т. 4. – №. 4. – С. 150-155.
5. Аллазов С. А., Камалов Н. А., Мурадова Р. Р. ЖИСТКОСТНЫЕ ОБЪЕМНЫЕ ОБРАЗОВАНИЯ ПОЧЕК (ОБЗОР ЛИТЕРАТУРЫ) //ЖУРНАЛ РЕПРОДУКТИВНОГО ЗДОРОВЬЯ И УРО-НЕФРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ. – 2021. – Т. 2. – №. 1.
6. Ибрагимов Б. Ф., Худоярова Д. Р., Кобилова З. А. Восстановление фертильности при синдроме поликистозных яичников //ВВК. – 2020. – Т. 79. – С. 551.
7. Ибрагимов Б., Худоярова Д. Перспективы диагностики синдрома поликистозных яичников //журнал биомедицины и практики. – 2021. – Т. 1. – №. 1. – С. 253-258.
8. Мурадова Р. Р., Хайдаров М. М. КЛИНИКО-ФАРМАКОЛОГИЧЕСКИЕ АСПЕКТЫ ПРИМЕНЕНИЯ ГОРМОНАЛЬНЫХ ПРЕПАРАТОВ В ОФТАЛЬМОЛОГИИ //Достижения науки и образования. – 2021. – №. 3 (75). – С. 100-102.

International Journal of Medical Sciences And Clinical Research (ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Publisher: Oscar Publishing Services

9. Мурадова Р. Р., Хайдаров М. М., Бегнаева М. У. Современные клинико-фармакологические аспекты применения нефротоксичных антибиотиков //Достижения науки и образования. – 2021. – №. 3. – С. 98-100.
10. Мурадова Р. Р., Хайдаров М. М. ФОТОТОКСИЧЕСКИЕ И ФОТОАЛЛЕРГИЧЕСКИЕ РЕАКЦИИ ПРИ ИСПОЛЬЗОВАНИИ СОВРЕМЕННЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ И НЕКОТОРЫХ РАСТЕНИЙ //Вопросы науки и образования. – 2020. – №. 37 (121). – С. 41-44.
11. Мурадова Р. Р., Хайдаров М. М., Омонов Э. М. ОПТИМИЗАЦИЯ ТЕРАПИИ БОЛЬНЫХ С ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМОЙ С УЧЕТОМ ПАРАМЕТРОВ СОСТОЯНИЯ МИКРОЦИРКУЛЯТОРНОГО РУСЛА ЦЕНТРАЛЬНОЙ ЗОНЫ СЕТЧАТКИ //Вопросы науки и образования. – 2021. – №. 10 (135). – С. 66-69.
12. Олимжонова Ф. и др. ДИЕТА И ОБРАЗ ЖИЗНИ ДО И ВО ВРЕМЯ БЕРЕМЕННОСТИ //Журнал академических исследований нового Узбекистана. – 2024. – Т. 1. – №. 1. – С. 47-50.
13. Тилявова С., Худоярова Д. Реалии времени. Синдром гиперактивного мочевого пузыря и пременопауза //Журнал биомедицины и практики. – 2021. – Т. 1. – №. 3/2. – С. 25-30.
14. Хапалюк А. В. КЛИНИКО ФАРМАКОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА ВИТАМИНОВ ГРУППЫ В //Научно-практический терапевтический журнал.
15. Хайдаров М. М., Мурадова Р. Р., Худойбердиева Г. С. Оптимизация премедикации при хирургических вмешательствах в гинекологии //Достижения науки и образования. – 2020. – №. 5 (59). – С. 98-102.
16. Хайдаров М. М., Мурадова Р. Р. Гепатотоксичность лекарственных средств как одна из проблем современной медицины //Наука через призму времени. – 2020. – №. 11. – С. 46-49.
17. Эшназарова Г. и др. ОСНОВНЫЕ ПОНЯТИЯ БИОТЕХНОЛОГИЧЕСКОГО ПОЛУЧЕНИЯ ЛЕКАРСТВ //Бюллетень студентов нового Узбекистана. – 2024. – Т. 2. – №. 2. – С. 11-15.
18. Шавкатова Г. Ш., Худоярова Д. Р. Оптимизация лечения метаболического синдрома //Проблемы современной науки и образования. – 2022. – №. 3 (172). – С. 54-57.
19. Шавкатова Г. Ш., Худоярова Д. Р., Абдуллаева Н. Н. МЕТАБОЛИЧЕСКИЙ СИНДРОМ И НОВЫЕ ВОЗМОЖНОСТИ ЕГО КОРРЕКЦИИ.
20. Шавкатова Г. Ш., Худоярова Д. Р. Проблемы современной науки и образования //Проблемы современной науки и

International Journal of Medical Sciences And Clinical Research (ISSN – 2771-2265)
VOLUME 04 ISSUE 05 PAGES: 36-41
SJIF IMPACT FACTOR (2022: 5. 893) (2023: 6. 184) (2024: 7.544)
OCLC – 1121105677
Publisher: Oscar Publishing Services

образования Учредители: Олимп. – Т. 3. – С. 54-57.